Insight Molecular Diagnostics Inc. — Director's Dealing 2015

Dec 30, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2015-12-30

Reporting Person: ANNETT WILLIAM (Director, President and CEO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$2.20	2025-01-08	Common Stock (5000)		Direct
Option to Purchase Common Stock	$2.20	2025-06-15	Common Stock (605000)		Direct

Footnotes

F1: Became exercisable in two equal installments based upon continued service on the board of directors from the date of grant.

F2: One quarter of the options shall vest upon the completion of 12 months of continuous employment from the date of grant on June 16, 2015 and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.